Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 3/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 3/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.35 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.35 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | PEPD | P12955 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026745 | 1.00 | ARG1 (0.41) | ARG1ARG2SLC7A5ANPEPRNPEP | |
| SCHEMBL13958625 | 0.84 | NR1H2 (0.38) | ARG1ARG2ANPEPRNPEPDNPEP | |
| SCHEMBL6580449 | 0.77 | NPFFR2 (0.46) | LARS1 | |
| SCHEMBL4450584 | 0.72 | CTSK (0.65) | CTSK | |
| SCHEMBL9928854 | 0.72 | MEN1 (0.37) | — | |
| SCHEMBL9928853 | 0.72 | MEN1 (0.37) | — | |
| SCHEMBL5096619 | 0.71 | CTSK (0.41) | ARG1ARG2SLC7A5LARS1MMP2 | |
| SCHEMBL5096613 | 0.71 | CTSK (0.41) | ARG1ARG2SLC7A5LARS1MMP2 | |
| SCHEMBL9928687 | 0.68 | CHRNB2 (0.31) | — | |
| SCHEMBL6127398 | 0.68 | CHRNB2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012011-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012011-A1 | Novel Compounds | TRPV4, TRPV1, TRPV3 | ARG1 2197/4885ARG2 1185/4885SLC7A5 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.